Phase 1/2 Leukemia clinical trials

46 recruiting Phase 1/2 leukemia studies in the US. What trial phases mean

Other phases

RecruitingPhase 1 / Phase 2NCT06364423

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 1 / Phase 2NCT07109219

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Sponsor: AstraZeneca

Duarte, CA · Jacksonville, FL · Chicago, IL · +3 more sites

RecruitingPhase 1 / Phase 2NCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Sponsor: AstraZeneca

Birmingham, AL · Duarte, CA · Los Angeles, CA · +9 more sites

RecruitingPhase 1 / Phase 2NCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Sponsor: Syndax Pharmaceuticals

Duarte, CA · Los Angeles, CA · Palo Alto, CA · +19 more sites

RecruitingPhase 1 / Phase 2NCT07128381

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT06129734

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Sponsor: Benjamin Tomlinson

Cleveland, OH

RecruitingPhase 1 / Phase 2NCT04140487

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT06235801

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT04925479

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Sponsor: Novartis Pharmaceuticals

Indianapolis, IN · Boston, MA · Jackson, MS · +5 more sites

RecruitingPhase 1 / Phase 2NCT06548230

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT03471260

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Sponsor: M.D. Anderson Cancer Center

Boston, MA · Cleveland, OH · Portland, OR · +1 more sites

RecruitingPhase 1 / Phase 2NCT03104491

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Sponsor: Leland Metheny

Westwood, KS · Boston, MA · Omaha, NE · +4 more sites

RecruitingPhase 1 / Phase 2NCT04049539

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Sponsor: Ohio State University Comprehensive Cancer Center

Sacramento, CA · Columbus, OH

RecruitingPhase 1 / Phase 2NCT05010122

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT05322850

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

Sponsor: University of Florida

Gainesville, FL · Miami, FL · +1 more sites

RecruitingPhase 1 / Phase 2NCT06523556

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Sponsor: Uma Borate

Columbus, OH

RecruitingPhase 1 / Phase 2NCT04726241

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Sponsor: PedAL BCU, LLC

Birmingham, AL · Mobile, AL · Anchorage, AK · +161 more sites

RecruitingPhase 1 / Phase 2NCT07311746

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT05092451

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT07008638

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Sponsor: Masonic Cancer Center, University of Minnesota

Minneapolis, MN

RecruitingPhase 1 / Phase 2NCT07155226

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Sponsor: AstraZeneca

Decatur, IL · New York, NY · Chapel Hill, NC · +3 more sites

RecruitingPhase 1 / Phase 2NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Sponsor: CellCentric Ltd.

Atlanta, GA · Indianapolis, IN · Bethesda, MD · +3 more sites

RecruitingPhase 1 / Phase 2NCT03670966

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase 1 / Phase 2NCT07356154

A Study of Revumenib and Mezigdomide in People With Leukemia

Sponsor: Memorial Sloan Kettering Cancer Center

Duarte, CA · Basking Ridge, NJ · Middletown, NJ · +7 more sites

RecruitingPhase 1 / Phase 2NCT04047641

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT05848687

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Sponsor: Tanja Andrea Gruber

Phoenix, AZ · Little Rock, AR · Los Angeles, CA · +14 more sites

RecruitingPhase 1 / Phase 2NCT04774393

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT07591649

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Sponsor: Masonic Cancer Center, University of Minnesota

Minneapolis, MN

RecruitingPhase 1 / Phase 2NCT06928662

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase 1 / Phase 2NCT04329728

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

Sponsor: AVM Biotechnology Inc

Duarte, CA · Los Angeles, CA · +8 more sites

RecruitingPhase 1 / Phase 2NCT06839456

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

Sponsor: Children's Hospital of Philadelphia

Philadelphia, PA

RecruitingPhase 1 / Phase 2NCT05674175

Co-administration of CART22-65s and huCART19 for B-ALL

Sponsor: Stephan Grupp MD PhD

Philadelphia, PA

RecruitingPhase 1 / Phase 2NCT05702853

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Sponsor: Medical University of South Carolina

Charleston, SC

RecruitingPhase 1 / Phase 2NCT05756322

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

Sponsor: Lin BioScience, Inc

Tampa, FL · Chicago, IL · Fairway, KS · +2 more sites

RecruitingPhase 1 / Phase 2NCT04988555

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sponsor: Sumitomo Pharma America, Inc.

Newport Beach, CA · Palo Alto, CA · Denver, CO · +30 more sites

RecruitingPhase 1 / Phase 2NCT04990102

Phase IB/II of CPX-351 for Relapse Prevention in AML

Sponsor: Georgetown University

Washington D.C., DC · Hackensack, NJ · Philadelphia, PA

RecruitingPhase 1 / Phase 2NCT06207123

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Sponsor: University of Chicago

Chicago, IL · Rochester, NY

RecruitingPhase 1 / Phase 2NCT07148180

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Sponsor: Jacqueline Garcia, MD

Boston, MA

RecruitingPhase 1 / Phase 2NCT07052695

Mosunetuzumab for CLL MRD Clearance

Sponsor: Inhye Ahn

Boston, MA

RecruitingPhase 1 / Phase 2NCT06680752

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Sponsor: ARCE Therapeutics, Inc.

Charlotte, NC · Winston-Salem, NC · Houston, TX

RecruitingPhase 1 / Phase 2NCT05643742

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Sponsor: CRISPR Therapeutics AG

Westwood, KS · St Louis, MO · San Antonio, TX · +1 more sites

RecruitingPhase 1 / Phase 2NCT04150497

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Sponsor: Cellectis S.A.

Los Angeles, CA · Aurora, CO · Denver, CO · +11 more sites

RecruitingPhase 1 / Phase 2NCT05503134

Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

Sponsor: Nationwide Children's Hospital

Columbus, OH

Not yet recruitingPhase 1 / Phase 2NCT07604233

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

Sponsor: M.D. Anderson Cancer Center

Houston, TX

Not yet recruitingPhase 1 / Phase 2NCT07847957

Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL

Sponsor: Dana-Farber Cancer Institute

Boston, MA

Not yet recruitingPhase 1 / Phase 2NCT07313852

A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

Sponsor: Memorial Sloan Kettering Cancer Center

New York, NY

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.